Loading...
Loading...
Impax Pharmaceuticals,the branded products division of Impax Laboratories, Inc.
IPXL, today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64^th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28. IPX066 is an investigational, patented extended release capsule formulation of carbidopa-levodopa intended for the treatment of idiopathic Parkinson's disease. IPX066 is being developed in collaboration with GlaxoSmithKline for territories countries outside the U.S. and Taiwan.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in